- Home
- SYTA vs KPTI Comparison
SYTA vs KPTI Comparison
Compare SYTA & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYTA
- KPTI
- Stock Information
- Founded
- SYTA N/A
- KPTI 2008
- Country
- SYTA Canada
- KPTI United States
- Employees
- SYTA N/A
- KPTI N/A
- Industry
- SYTA Telecommunications Equipment
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- SYTA Telecommunications
- KPTI Health Care
- Exchange
- SYTA Nasdaq
- KPTI Nasdaq
- Market Cap
- SYTA 38.2M
- KPTI 44.5M
- IPO Year
- SYTA 2020
- KPTI 2013
- Fundamental
- Price
- SYTA $3.03
- KPTI $6.31
- Analyst Decision
- SYTA
- KPTI Buy
- Analyst Count
- SYTA 0
- KPTI 6
- Target Price
- SYTA N/A
- KPTI $39.80
- AVG Volume (30 Days)
- SYTA 658.1K
- KPTI 204.3K
- Earning Date
- SYTA 08-14-2025
- KPTI 08-11-2025
- Dividend Yield
- SYTA N/A
- KPTI N/A
- EPS Growth
- SYTA N/A
- KPTI N/A
- EPS
- SYTA N/A
- KPTI N/A
- Revenue
- SYTA $11,883,835.00
- KPTI $137,269,000.00
- Revenue This Year
- SYTA $18.41
- KPTI $2.18
- Revenue Next Year
- SYTA N/A
- KPTI $11.28
- P/E Ratio
- SYTA N/A
- KPTI N/A
- Revenue Growth
- SYTA 49.13
- KPTI N/A
- 52 Week Low
- SYTA $0.93
- KPTI $3.51
- 52 Week High
- SYTA $29.20
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- SYTA 43.98
- KPTI 67.33
- Support Level
- SYTA $2.50
- KPTI $6.02
- Resistance Level
- SYTA $3.85
- KPTI $7.01
- Average True Range (ATR)
- SYTA 0.29
- KPTI 0.62
- MACD
- SYTA -0.07
- KPTI 0.23
- Stochastic Oscillator
- SYTA 39.29
- KPTI 79.17
About SYTA Siyata Mobile Inc.
Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.